Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1,051 - 1,100 out of 12,335

Document Document Title
WO/2004/028462A9
The present invention is a method for preparing 2-halo-6-aminopurines, and more specifically for preparing the clinical agent cladribine (2-chloro-2'-deoxyadenosine, C1dAdo, 4), a drug of choice against hairy-cell leukemia and other neop...  
WO/2010/093608A1
Provided are thieno[3,4-d]pyrimidin-7-yI and furo[3,4-d]pyrimidin-7-yl ribosides, riboside phosphates and prodrugs thereof as well as intermediates and methods of preparation. The compounds, compositions, and methods provided are useful ...  
WO/2010/003540A3
The present invention relates to an in-vitro method for the formation of megamitochondria in cells, wherein the cells are grown in a suitable fermentation medium acidulated with lactic acid to pH values between 5.3 and 6.7. The invention...  
WO/2010/090969A1
The present disclosure describes tetrahydropyran nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, novel tetrahydropyran nucleoside analogs are provided having a...  
WO/2010/082128A1
The present invention relates to a novel and stereoselective synthetic process for the preparation of optically active cis-nucleoside derivatives of compound of Formula (I), wherein R3 represents H, F, Cl, C1-16 alkyl.  
WO/2010/079813A1
Provided is a method for efficiently manufacturing an inosine derivative represented by the general formula (8). (8) The method for manufacturing the inosine derivative (8) includes steps (a)-(d). Step (a): An inosine derivative (3) is m...  
WO/2010/081082A2
Phosphoramidate compounds derived from guanine bases having enhanced therapeutic potency are provided, and these compounds in particular have enhanced potency with respect to treatment of viral infections, such as hepatitis C virus. Phar...  
WO/2010/077578A1
The present disclosure describes bis-modified bicyclic nucleosides and oligomeric compounds that can be prepared comprising at least one of these bis-modified bicyclic nucleosides. More particularly, the bis-modified bicyclic nucleosides...  
WO/2010/075554A1
A process for preparing phosphoramidate prodrugs or cyclic phosphate prodrugs of nucleoside derivatives, which is a compound, its stereoisomers, salts (acid or basic addition salts), hydrates, solvates, or crystalline forms thereof.  
WO/2010/072146A1
The invention provides an isonucleoside compound which can significantly enhance the gene silencing efficiency of oligonucleotide modified by it and can keep the enzymatic stability of the oligonucleotide. The invention also provides a m...  
WO/2010/075517A2
A purified compound having activity against hepatitis C virus is disclosed.  
WO/2010/069047A1
The sialic acid-like sugar legionaminic acid is found as a virulence-associated surface glycoconjugate in Legionella pneumophila and Campylobacter coli. In this work, we have purified and biochemically characterized eleven candidate bios...  
WO/2010/066666A1
A process is disclosed for the production of cyclic di-guanosine monophosphate (c-di-GMP) without the use of protecting groups by means of an enzymatic synthesis. The process comprises the coupling of two guanosine triphosphate (GTP) mol...  
WO/2010/066970A1
The invention relates to novel compounds having flavour enhancer properties, to a method for obtaining these novel compounds, and to use of these compounds as flavour enhancers.  
WO/2010/066699A1
Compounds of the formula (I) including any possible stereoisomers thereof, wherein: R1 is hydrogen or halo; R4 is a monophosphate, diphosphate or triphosphate ester; or R4 is a group of formula (II) R7 is optionally substituted phenyl; n...  
WO/2010/065671A2
Oligonucleotide compounds modulate expression and/or function of Vascular Endothelial Growth Factor (VEGF) polynucleotides and encoded products thereof. Methods for treating diseases associated with Vascular Endothelial Growth Factor (VE...  
WO/2010/063080A1
Amphiphilic prodrugs of general formula A-X are disclosed, wherein A is a biologically active agent or may be metabolised to a biologically active agent; and X is selected from the group consisting of R, or up to three R moieties attache...  
WO/2010/065787A2
The present invention relates to antisense oligonucleotides that modulate the expression of and/or function of Tumor Suppressor genes, in particular, by targeting natural antisense polynucleotides of Tumor Suppressor genes. The invention...  
WO/2010/027512A3
The present invention relates to novel phosphoramidites, A-n-bz, C-n-bz, C-n-ac, G-n-ac and U are produced with an HPLC purity of greater than 98% and 31P NMR purity greater than 99%. A novel process of reverse 5'→ 3' directed synthesi...  
WO/2010/065852A1
This invention provides for novel antiparasitic and pesticidal derivatives of avermectin and milbemycin compounds in which two avermectin or milbemycin members are linked together by a chemical linker. The resulting compounds may be used...  
WO/2010/065662A2
Oligonucleotide compounds modulate expression and/or function of Sirtuin 1 (SIRT1) polynucleotides and encoded products thereof. Methods for treating diseases associated with Sirtuin 1 (SIRT1) comprise administering one or more Oligonucl...  
WO/2010/065444A1
The invention describes a cytotoxic composition containing a drug combination targeting two or more functional elements in pancreatic cancer cells, the functional elements comprising EGFR or Src and Stat3 or Jaks. Preferred drugs in the ...  
WO/2010/062404A2
This invention relates to synthesis of novel -N-FMOC protected nucleosides, succinates, phosphoramidites, corresponding solid supports that are suitable for oligo deoxy nucleosides and RNA oligonucleotide synthesis. Our discovery using N...  
WO/2010/061402A2
The present invention direct to an improved process for the preparation of the compound 5-deoxy -2, 3-O-isopyridene -N-[(pentyloxy) carbonyl]-5- fluorocystidine of the formula (I).  
WO/2008/121634A3
Disclosed herein are phosphoramidate prodrugs of nucleoside derivatives for the treatment of viral infections in mammals, which is a compound, its stereoisomer, salt (acid or basic addition salt), hydrate, solvate, or crystalline form th...  
WO/2010/036407A3
The invention provides compounds as described herein, as well as pharmaceutical compositions comprising the compounds, and synthetic methods and intermediates that are useful for preparing the compounds. The compounds are useful as anti-...  
WO/2010/057185A1
The present invention provides labeled phospholink nucleotides that can be used in place of naturally occurring nucleotide triphosphates or other analogs in template directed nucleic acid synthesis reactions and other nucleic acid reacti...  
WO/2010/054032A2
Methods and apparatus for facilitating the synthesis of compounds in a batch device are presented. Application of the batch type microfluidic devices to the synthesis of radiolabeled compounds is described. These methods and apparatus en...  
WO/2010/049611A1
The invention relates to a new type of polysaccharide-block-polypeptide diblock copolymer which is bioresorbable or biodegradable and biocompatible, to a method for preparing same, to the micellar vesicles constituted of this copolymer, ...  
WO/2009/139719A9
The present invention relates to novel synthesis routes for preparation of thiodigalactosides of the general formula (12). The method comprises the use of a 3-azido-galactosyl thiouronium salt derivative, which is activated to the corres...  
WO/2010/011312A9
This invention provides methods of derivatizing a double-stranded DNA comprising contacting double-stranded DNA with a CpG methyltransf erase and an s-adenosylmethionine analog. This invention also provides methods of sequencing DNA to d...  
WO/2010/005799A3
Novel compounds and methods of using the same to inhibit glycolysis and treat cancer and other diseases are provided herein.  
WO/2008/142055A3
A compound of formula (I) and pharmaceutically acceptable salts thereof; compositions containing it and its use in medicine, particularly for the treatment or inhibition of HCV infections, and processes for making it are disclosed.  
WO/2009/143369A3
Provided herein are methods for preparing purified modified nucleosides from reaction mixtures using precipitation as opposed to traditional chromatographic methods. The methods are particularly amenable to protected nucleosides and nucl...  
WO/2010/040286A1
The invention discloses triacetyl-3-hydroxyphenyladenosine represented by formula (I), the preparation, the pharmaceutical composition and the use thereof. Specially, the invention discloses a new compound of 2’,3’,5’-tri-O-acetyl-...  
WO/2010/037179A1
The invention relates to anionic conjugates of glycosylated bacterial metabolites that may be used to mimic the structure and/or activity of the anionic bioactive molecules known as glycosaminoglycans (GAGs). The invention also relates t...  
WO/2010/038874A1
Disclosed are: an anti-XDR-TB agent having excellent pharmacological efficacy against extremely drug-resistant tuberculosis bacteria; an anti-MDR-TB agent having excellent pharmacological efficacy against multi-drug-resistant tuberculosi...  
WO/2010/017547A8
A process of synthesizing a 5-azacytosine nucleoside, such as azacitidine and decitabine, comprises coupling a silylated 5-azacytosine with a protected D-ribofuranose of formula in the presence of a sulfonic acid catalyst.  
WO/2010/036698A1
The present disclosure describes substituted α-L-bicyclic nucleoside analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, substituted α-L-bicyclic nucleoside analogs are pro...  
WO/2009/037592A3
Aminoglycoside-amino acid and -peptide conjugates comprising a triazolyl linker are provided along with efficient methods of their preparation. The aminoglycoside may be an aminoglycoside antibiotic. Conjugates comprising an aminoglycosi...  
WO/2010/036213A1
This invention describes the series of compounds based on the 3-deazaneplanocin A (DZNep) core structure designed to inhibit the function of Polycomb repressive complex 2 (PRC2) proteins.  
WO/2010/036696A1
The present disclosure describes cyclohexenyl nucleic acid analogs, oligomeric compounds prepared therefrom and methods of using the oligomeric compounds. More particularly, cyclo- hexenyl nucleic acid analogs are provided, having one or...  
WO/2010/031954A1
The invention relates to a method for preparing 1,6:2,3-dianhydro-β-D-mannopyranose and is characterized in that it includes a step of cyclizing the compound B, where R is an activating agent, in the presence of a base selected from amo...  
WO/2010/031953A1
The invention relates to a method for preparing 1,6:2,3-dianhydro-â-D-mannopyranose and is characterized in that it includes a step of cyclizing the compound C, where R is an alkyl group and R' is an activating agent, in an alcohol/alco...  
WO/2010/029574A2
An improved process for preparing gemcitabine or salts thereof, comprising the following steps, dissolved 2-Deoxy-2,2- difluoro-D-ribofuranose-3,5-dibenzoate in an organic solvent and allowed to cool to 0 to 10 degree centigrade temperat...  
WO/2010/028781A1
The present invention relates to new 8-substituted (Formula I) and 6, 8-disubstituted 2' -deoxyguano- sines (Formula I) and precursors for preparing these as well as methods for preparing said compounds and precursors. Moreover, the pres...  
WO/2009/142822A3
This invention relates to a method of modulating the expression of a target gene in an organism comprising administering an iRNA agent, wherein the iRNA comprises at least one 2'-deoxy-2'-fluoro (2'-F) nucleotide in the antisense strand ...  
WO/2010/026490A1
Embodiments of the present disclosure relate generally to reporter compositions which are synthetic nucleotides that comprise nucleotides with a high charge mass moiety attached thereto via a linker molecule. The linker molecules can var...  
WO/2010/027005A1
A compound represented by general formula (I) [wherein --- represents a single bond or a double bond; L represents –NH- or the like; X1 represents N or C, provided that in the case where X1 is N, X2 represents C-R and in the case where...  
WO/2010/025566A1
The present invention is directed to RNA monomers comprising O-acetal levulinyl protecting groups at the 2' and/or the 5'-hydroxy functionalities of the ribose moiety. Said monomers may be incorporated into oligoribonucleotides or RNA po...  

Matches 1,051 - 1,100 out of 12,335